Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 68.6% in June

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 29,900 shares, a decrease of 68.6% from the June 15th total of 95,100 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average daily volume of 82,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro as of its most recent SEC filing. 49.61% of the stock is owned by hedge funds and other institutional investors.

Alzamend Neuro Trading Down 3.3 %

Shares of NASDAQ ALZN opened at $0.41 on Friday. The firm’s 50-day moving average price is $0.51 and its 200-day moving average price is $0.77. Alzamend Neuro has a 1-year low of $0.37 and a 1-year high of $8.10. The firm has a market capitalization of $3.29 million, a P/E ratio of -0.42 and a beta of 0.03.

Shares of Alzamend Neuro are going to reverse split on the morning of Tuesday, July 16th. The 1-10 reverse split was announced on Tuesday, July 16th. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, July 16th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.